Clinical Study on Zero Out-of-Pocket Carbon Ion Therapy for Liver Cancer Fully Launched

Clinical Study on Zero Out-of-Pocket Carbon Ion Therapy for Liver Cancer Fully Launched

As the first hospital in China to clinically apply a domestic heavy ion system and the only hospital globally operating two heavy ion systems, Gansu Wuwei Cancer Hospital has accumulated five years of clinical experience, treating over 2,000 patients across more than 50 conditions, including lung cancer, pancreatic cancer, and liver cancer. Clinical efficacy and patient survival rates have reached internationally advanced levels. The hospital has achieved "eight world and domestic firsts": the only hospital globally operating two heavy ion therapy systems; the hospital with the highest number of single-fraction treatments completed within one day; the first globally to develop precision heavy ion therapy under respiratory control; the first globally to implement bladder cancer treatment with precise bladder volume management; the first globally to perform single-session heavy ion therapy using surgically placed spacers between organs and tumors; the first in China to develop a 360° rotatable and adjustable ion therapy chair; the first globally to complete multiple cases of cardiac tumor treatment with heavy ions; and the first globally to integrate heavy ion therapy with comprehensive, lifelong physical and mental health management.

To further advance the high-quality development of heavy ion therapy in China, the hospital will deepen clinical research and drive technological upgrades based on prior achievements. The "Clinical Study on Carbon Ion Radical Therapy for Early and Intermediate-Stage Hepatocellular Carcinoma" has now been launched, aiming to establish China’s clinical standards for heavy ion therapy in liver cancer, aligned with international benchmarks, to pursue better patient outcomes.

​​Clinical Study on Carbon Ion Radical Therapy for Early and Intermediate-Stage Hepatocellular Carcinoma​

Our hospital is conducting a Phase II clinical study on carbon ion radiotherapy for early and intermediate-stage hepatocellular carcinoma (HCC). Clinical trial registration number: ​​WW-TLZ-2025-001​​. Carbon ion therapy is an internationally advanced precision radiotherapy technology that can accurately target and destroy tumor cells while minimizing damage to surrounding healthy tissues. This study aims to evaluate the safety and efficacy of this technology, exploring better treatment options for liver cancer patients.

Eligibility Criteria​

1. Age 18–75 years, with pathologically confirmed HCC.

2. Tumor stage: early or intermediate (BCLC Stage A or B, without extrahepatic metastasis).

3. Good liver function (Child-Pugh Class A or B, score ≤7).

4. No prior liver radiotherapy, surgery, or other local radical treatments.

5. Voluntary participation and ability to comply with treatment and follow-up requirements.

The above criteria are primary screening standards; final eligibility will be determined by the investigators based on the trial protocol.

​​Patient Benefits​

1. The hospital will provide research funding to cover the carbon ion therapy costs.

2. A multidisciplinary expert team (MDT) will develop a personalized treatment plan.

3. Regular follow-up monitoring for up to 3 years post-treatment, with priority access to new therapies.

Contact Information​

Wuwei Heavy Ion Center, Gansu Wuwei Cancer Hospital​​

   Ma Youguo: +86 136 3935 9095

​​Lanzhou Heavy Ion Center, Gansu Wuwei Cancer Hospital​​

   Qi Ying: +86 139 9350 3180